Syndax, Incyte Announce Topline Results From AGAVE-201 Trial Of Axatilimab In Chronic Graft-versus-host Disease, Meeting Its Primary Endpoint Across All Cohorts With An Overall Response Rate Of 74% At A Dose Of 0.3 Mg/Kg Administered Every Two Weeks
Portfolio Pulse from Benzinga Newsdesk
Syndax and Incyte have announced positive topline results from the AGAVE-201 trial of Axatilimab in chronic graft-versus-host disease. The trial met its primary endpoint across all cohorts with an overall response rate of 74% at a dose of 0.3 mg/kg administered every two weeks.
July 24, 2023 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive results from the AGAVE-201 trial could potentially boost Incyte's stock in the short term.
Positive clinical trial results often lead to increased investor confidence and can drive up a company's stock price. Given that Incyte is one of the companies behind the trial, it's likely that this news will have a positive impact on its stock.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
The positive results from the AGAVE-201 trial could potentially boost Syndax's stock in the short term.
Positive clinical trial results often lead to increased investor confidence and can drive up a company's stock price. Given that Syndax is one of the companies behind the trial, it's likely that this news will have a positive impact on its stock.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50